StockNews.AI
CRVS
StockNews.AI
155 days

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

1. Corvus Pharmaceuticals will hold conference call on March 25, 2025. 2. The call will report Q4 and full year 2024 financial results. 3. Company focuses on ITK inhibition for cancer immunotherapy. 4. Soquelitinib is the lead product candidate in development. 5. Financial results could significantly drive investor interest.

3m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial results could reveal positive performance, similar to previous quarters where announcements led to price increases.

How important is it?

The conference call could highlight advances in drug development and financial health, crucial for investor confidence.

Why Short Term?

The conference call on March 25 may produce immediate investor reactions, as financial updates often do.

Related Companies

MRNABMYNVS
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT March 17, 2025 16:01 ET  | Source: Corvus Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 25, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days. About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com. INVESTOR CONTACT:Leiv LeaChief Financial OfficerCorvus Pharmaceuticals, Inc.+1-650-900-4522llea@corvuspharma.com MEDIA CONTACT:Sheryl SeapyReal Chemistry+1-949-903-4750sseapy@realchemistry.com

Related News